Full-Time

Ecoa Standards Manager

Posted on 4/9/2025

argenx

argenx

1,001-5,000 employees

Biotechnology for autoimmune disease treatments

No salary listed

Senior, Expert

Boston, MA, USA + 1 more

More locations: Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Knowledge of ICH-GCP and other applicable legislation
  • CDISC standards (SDTM)
  • Eye for detail, analytical skills
  • Able to work independently
  • Strong communication and interpersonal skills
  • Fluent in English (written and spoken)
  • Master’s or Bachelor’s degree in Biomedical or similar, or equivalent by experience
  • At least 8 years experience in Clinical Data Management (Biotech experience is a plus)
  • Experience with eCOA data as Subject Matter Expert in a biotech or pharma organization
  • Knowledge of (e)COA processes and systems
  • Experience of working in a Data Standards team
  • In depth understanding of Clinical Development processes
  • Good knowledge of the applicable regulatory guidelines
Responsibilities
  • Take a leadership role in cross-functional teams to create standards for eCOA data, standardized Data Transfer Agreements (DTA’s) and (SDTM) data mappings.
  • Support portfolio on all aspects of eCOA data ingestion, standardization, linking with clinical endpoints, etc.
  • Ensures CDISC compliant mapping of COA data by creating & maintaining a library of SDTM metadata for COA’s.
  • Serve as Lead for eCOA technology / systems and integrations
  • Escalation point for study-specific eCOA 'DM-related' issues.
  • Serve as eCOA Lead for argenx Near Real Time Data Flow i.e. weekly eCOA vendor transfers for internal SDTM creation; QC & insight generation tools.
  • Provide support to optimize data acquisition process in clinical trials by exploring opportunities to streamline and integrate data, enhancing efficiency and data quality.
  • Stay abreast of regulatory requirements and new industry trends and technologies concerning COAs, and inform relevant stakeholders if needed.
  • Participate in regulatory agency inspections and internal audits, when appropriate.

argenx develops immunology solutions aimed at treating severe autoimmune diseases and cancer. The company focuses on creating therapeutic antibodies, with a notable product being cusatuzumab, which is in development with Janssen R&D to address hematological malignancies like leukemia. argenx collaborates with academic institutions and industry partners to turn scientific research into viable treatments. Its business model emphasizes research and development, followed by licensing agreements and partnerships for bringing products to market. Revenue is generated through milestone payments, royalties, and sales of its products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive CHMP opinion for VYVGART in CIDP could capture significant European market share.
  • Phase 2 trial of cusatuzumab in AML enhances argenx's oncology pipeline.
  • FDA priority review for VYVGART Hytrulo indicates potential accelerated U.S. market entry.

What critics are saying

  • Increased competition in autoimmune disease treatment could impact argenx's market share.
  • Potential delays in clinical trial timelines due to regulatory changes in key markets.
  • Dependence on key partnerships poses risk if collaborations face challenges or termination.

What makes argenx unique

  • Argenx focuses on innovative immunology solutions for autoimmune diseases and cancer.
  • The company collaborates with academic institutions and industry partners for therapeutic antibody development.
  • Cusatuzumab, developed with Janssen R&D, targets hematological malignancies like leukemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

0%
PharmiWeb
May 1st, 2025
Argenx Announces Positive Chmp Opinion For Vyvgart (Efgartigimod Alfa) Subcutaneous Injection For Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trialEuropean Commission (EC) decision on marketing authorization application (MAA) expected within approximately two monthsAmsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.“Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. The positive CHMP opinion for VYVGART in CIDP brings us one step closer to providing patients across Europe with a transformational new treatment option that provides meaningful functional improvement,” said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. “VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and if approved, would mark the first treatment in Europe with a novel, precision mechanism of action for CIDP patients in 30 years.”VYVGART for subcutaneous injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. Treatment is initiated with a weekly dose regimen and may be adjusted to every other week based on clinical evaluation.The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. In the ADHERE study, 66.5% (214/322) of patients treated with VYVGART, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo

Stock Titan
Feb 25th, 2025
argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference.

Business Wire
Nov 22nd, 2024
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML

Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML

Clinical Trial Vanguard
Nov 20th, 2024
Steritas & Argenx Announce Collaboration to Advance Steroid-Sparing Therapeutics

Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company Argenx.

BioSpace
May 9th, 2024
Argenx Reports First Quarter 2024 Financial Results And Provides Business Update

$398 million in first quarter global net product sales. FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024. On track to submit filing for pre-filled syringe (PFS) in second quarter 2024

INACTIVE